Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Kris, Mark G ^k   Tonato, Maurizio ^a   Bria, Emilio ^a   Ballatori, Enzo ^b   Espersen, Birgitte ^c   Herrstedt, Jørn ^d   Rittenberg, Cynthia ^e   Einhorn, Lawrence H ^f   Grunberg, Steven ^g   Saito, Mitsue ^h   Morrow, Gary ⁱ   Hesketh, Paul ^j  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Azienda Opedaliera   (Italy)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e Rittenberg Oncology Consulting   (United States)

^f WALTHER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h JUNTENDO UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^k NONE

more..

Author keywords

Antiemetic agents; High emetic risk chemotherapy; Nausea

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; FOSAPREPITANT; GRANISETRON; ONDANSETRON; PALONOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON;

CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; HIGH EMETIC RISK CHEMOTHERAPY; HUMAN; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; NAUSEA; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 79953297050     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0976-9     Document Type: Review

References (59)

1. Aapro M, Selak M, Lichinitser D, Santini A, Macciocchi A, Klinik A, Blokhin NN (2003) Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a Phase III trial. Proc Am Soc Clin Oncol 22:726
2. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449 (Pubitemid 44400384)
3. Andrews PLR, Davis CJ (1993) The mechanism of emesis induced by anti-cancer therapies. In: Andrews PLR, Sanger GJ (eds) Emesis in anticancer therapy mechanisms and treatment. Chapman & Hall, London, pp 14-17
4. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975 (Pubitemid 23064211)
5. Blum RA, Majumdar A, McCrea J et al (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407-1419 (Pubitemid 36677284)
6. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300 (Pubitemid 36444075)
7. Chevalier B (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26:S33-S36
8. Cocquyt V, VanBelle S, Reinhardt RR, Decramer MLA, O'Brien M, Schellens JHM, Borms M, Verbeke L, VanAelst F, DeSmet M, Carides AD, Eldridge K, Gertz BJ (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754-030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842
9. DeMulder PH, Seynaeve C, Vermorken JB, Van Liessum LPA, Mols JS, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834-840
10. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Palonosetron study G. improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482 (Pubitemid 37466663)
11. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15:330-337 (Pubitemid 38262636)
12. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind placebo-controlled, comparative study. Ann Oncol 6:661-666 (Pubitemid 28318201)
13. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577 (Pubitemid 37304615)
14. Gralla RJ, Raftopoulos H, Bria E, ete al (2008) Cisplatin in non-small cell lung cancer: reducing the most prominent toxicity, emesis. Results of a meta-analysis with 1527 patients in randomized clinical trials testing the addition of an NK1 antagonist J Clin Oncol 26.
15. Gralla RJ, Tyson LB, KrisMG, Clark RA(1987) Themanagement of chemotherapy-induced nausea and vomiting. Med Clin North Am 71:289-301
16. Grunberg SM, Hesketh PJ, Carides AD et al (2003) Relationships between the incidence and control of cisplatin-induced acute vomiting and delayed vomiting: Analysis of pooled data from two phase III studies of the NK-1 antagonist aprepitant. Proc Am Soc Clin Oncol 22:2931a
17. Grunberg SM, Stevenson LL, Russell CA, McDermed JE (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137-1141 (Pubitemid 19196539)
18. Grunberg SM, Vanden Burgt JA, Berry S, et al (2004) Prevention of delayed nausea and vomiting (D-CNV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO).
19. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728
20. Heron JF (1995) Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22:24-30
21. Herrstedt J (1996) New perspectives in antiemetic treatment support care. Cancer 4:416-419
22. Hesketh PA, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF (1996) Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide Support Care Cancer 4.
23. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494
24. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
25. Hesketh PJ, Gandara DR, Hainsworth J, Edelman M, Webber LM, McManus M (1996) Addition of the dopamine D2 antagonist prochlorperazine to granisetron/dexamethasone: improved control of acute emesis fron high-dose cisplatin. Proc Am Soc Clin Oncol 15:540
26. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338-343 (Pubitemid 29022412)
27. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705 (Pubitemid 19145589)
28. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074-1080 (Pubitemid 36555864)
29. IGAR (1995) Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 13:2417-2426
30. IGAR (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatininduced acute emesis. J Clin Oncol 16:2937-2942
31. Ioannidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 18:3409-3422
32. Jordan K, Schmoll HJ, Aapro MS (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61:162-175 (Pubitemid 46073781)
33. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD (1996) Are more antiemetic trials with placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78:2193-2198 (Pubitemid 26367614)
34. Kris MG, Gralla RJ, Clark RA, Tyson LB, OConnell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384 (Pubitemid 15244935)
35. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. results of consecutive trials in 255 patients. Cancer 55:527-534 (Pubitemid 15156019)
36. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049 (Pubitemid 24145335)
37. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy Support Care. Cancer 13:85-96
38. Kris MG, PistersKMW, Hinkley L (1994) Delayed emesis following anticancer chemotherapy support care. Cancer 2:297-300
39. Kris MG, Radford J, Pizzo B, et al (1996) Dose ranging antiemetic trial of the NK-1 receptor antagonist CP-122,721: A new approach for acute and delayed emesis following cisplatin Proc Am Soc Clin Oncol: 547
40. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. Br J Clin Pharmacol 47:834-840
41. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174-1178 (Pubitemid 28108755)
42. MartyM, J-p K, Fournet P, Vergnenegro A, Carics P, Loria-Kanza Y, Simonetta C, Bruijn KM(1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anticancer Drugs 6:15-21
43. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade LE, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
44. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248
45. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, Huffman DH, Gould JR, Carron G, Ossi M, Anderson EM (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408-2416
46. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Gtote T, Carides AD, Gertz BJ (1999) Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist (Letter-authors reply). N Engl J Med 340:1927-1928
47. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxyoyptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043
48. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
49. Riviere A, on behalf of the Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971
50. Roila F, Del Favero A, Gralla RJ, Tonato M (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol 9:811-819 (Pubitemid 28440438)
51. Ruff P, Paska W, Goedhals L, Pouiliart P, Riviere A, on behalf of the Granisetron Study Group, Vorolieof D, Bloch, Jones A, Martin L, Brunet R, Butcher, Forster J, McQuade B, on behalf of the Ondansetron and Granisetron Emesis Study Group (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 51:113-118 (Pubitemid 24008652)
52. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial the lancetcom/oncology.
53. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, ChristmannD, SchmidtM,Kitchener H, pacs D, de Mulder PHM, on behalf of the Ondansetron Study Group (1992) Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 66:192-197
54. Soukop J, on behalf of the Granisetron Study Group (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin Support Care. Cancer 2:177-183
55. Soukop M, McQuade B, Hunter E et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304
56. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ (1994) Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin receptor antagonist CP-99,994. Neuropharmacology 33:259-260
57. Thant M, Pendergras K, Harman G, Modiano M, Martin L, DuBois D, Cramer M, Hahne W (1996) Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin chemotherapy (CCT). Proc ASCO 15:533
58. Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37:2398-2404 (Pubitemid 33097477)
59. VanBelle S, Lichinitser MR, Navari RM, Garin AM, Decramer MLA, Rivier A, ThantM, Brestan E, Bui B, Eldridge K, DeSmetM, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758-298 and MK-869. Amer Cancer Soc 94:3032-3041 (Pubitemid 34547705)